How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Exclusive: Campaign group calls on institutional shareholders to vote against re-election of bosses overseeing net zero row-back Bank chairs who water down their lenders’ climate commitments this year ...

The Trump administration in recent weeks has shifted its immigration enforcement rhetoric and tactics following the deaths of two U.S. citizens in Minnesota. Hundreds of Swiss bank accounts with ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The funding discussions highlight ongoing investor demand for new and unproven research labs looking to find novel approaches to AI that push the technology forward. Recursive’s goal is to develop ...

Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...

Canadian Prime Minister Mark Carney has refuted claims that he retracted his statements made at the World Economic Forum in Davos, Switzerland, during a recent conversation with President Donald Trump ...

SAN FRANCISCO -- One new startup is called Recursive with an "e." Another is called Ricursive with an "i." They are trying to do the same thing: Build artificial intelligence that can improve itself ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...